Teva Launches Generic for EpiPen Jr
August 20, 2019 – Teva has announced the launch of its generic for Mylan’s EpiPen Jr® (epinephrine 0.15mg) auto-injector. The product is indicated to provide emergency treatment of allergic reactions (Type I) including anaphylaxis.
Demand for epinephrine injectors tends to rise in late summer and early fall as parents and school districts prepare for the chance that a child may require emergency treatment for an allergic reaction while at school. At the same time, Mylan continues to face supply issues that have led to shortages of its epinephrine products. Amneal Pharmaceuticals, the manufacturer of Adrenaclick® (epinephrine injection), also expects to see shortages this year.
Intended for patients who weigh 15-30kg (33-66 pounds), epinephrine injection 0.15mg should be administered intramuscularly (IM) or subcutaneously (SC) to the middle of the outer thigh immediately in an allergic emergency. Caregivers of young children who may move during the process should be instructed to hold the leg firmly in place before and during the injection to reduce the risk of injury. In conjunction with the injection, patients should receive immediate medical or hospital care. Repeat injection may be required in the case of severe, persistent anaphylaxis.
Teva’s epinephrine injection 0.15mg carries a list price of $300 for a two-pack, similar to the list price for a two-pack of Mylan’s authorized generic for the EpiPen Jr and approximately half the list price of the brand name product.